Contents

Current Pharmaceutical Design, Volume 21 - Number 26

Meet Our Editorial Board Member

, 21(26): 3697

D. A. Butterfield


DOI: 10.2174/138161282126150827115238




Editorial

Editorial (Thematic Issue: Current Approaches for Antipsychotics in Drug Discovery: Hope Beyond the Dopamine D2 Receptor?)

, 21(26): 3698 - 3699

Ronan Depoortère


DOI: 10.2174/138161282126150827115924




Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics

, 21(26): 3700 - 3724

Robert R. Luedtke, Claudia Rangel-Barajas, Mahinder Malik, David E. Reichert and R. H. Mach


DOI: 10.2174/1381612821666150724100830




Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs

, 21(26): 3725 - 3731

Andrew C. McCreary and Adrian Newman-Tancredi


DOI: 10.2174/1381612821666150605105215




Atypical antipsychotics and inverse agonism at 5-HT2 receptors

, 21(26): 3732 - 3738

Laura C. Sullivan, William P Clarke and Kelly A. Berg


DOI: 10.2174/1381612821666150605111236




5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia

, 21(26): 3739 - 3759

Natasja M.W.J. de Bruin and Chris G Kruse


DOI: 10.2174/1381612821666150605112105




Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?

, 21(26): 3760 - 3770

Bart A. Ellenbroek and Bibinaz Ghiabi


DOI: 10.2174/1381612821666150605105325




Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?

, 21(26): 3771 - 3787

Philipp Singer, Sylvain Dubroqua and Benjamin K. Yee


DOI: 10.2174/1381612821666150724100952




When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy

, 21(26): 3788 - 3796

Gerard J. Marek


DOI: 10.2174/1381612821666150605105632




Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker

, 21(26): 3797 - 3806

Kenji Hashimoto


DOI: 10.2174/1381612821666150605111345




Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins

, 21(26): 3807 - 3812

Guy Griebel


DOI: 10.2174/1381612821666150605105859




Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction

, 21(26): 3813 - 3828

Marlies Van Duinen, Olga A.H. Reneerkens, Lena Lambrecht, Anke Sambeth, Bart P.F. Rutten, Jim Van Os, Arjan Blokland and Jos Prickaerts


DOI: 10.2174/1381612821666150605110941




Atrial Fibrillation and Gastro-Oesophageal Reflux Disease - Controversies and Challenges

, 21(26): 3829 - 3834

Mariana Floria, Oana Barboi, Ciprian Rezus, Valentin Ambarus, Cristina Cijevschi-Prelipcean, Gheorghe Balan and Vasile Liviu Drug


DOI: 10.2174/1381612821666150319100003




Efficacy of Andolast in Mild to Moderate Asthma: A Randomized, Controlled, Double-Blind Multicenter Study (The Andast Trial)

, 21(26): 3835 - 3843

Mario Malerba, Massimo D`Amato, Alessandro Radaeli, Giampaolo Giacovelli, Lucio Rovati, Sayed H. Arshad and Stephen T. Holgate


DOI: 10.2174/1381612821666150407101614




Research Article

Mechanisms of Improvement of Left Ventricular Function by Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Infusion in Very Old Patients with Coronary Chronic Total Occlusion

, 21(26): 3844 - 3850

Xia Li, You-dong Hu, Ying Chen, Hua-lan Zhou, Feng-lin Zhang, Dian-xuan Guo and Qing-na Zhao


DOI: 10.2174/1381612821666150724115406




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science